Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics
Authors:
- Deborah FincoDFDeborah Finco
- Daniel BaltrukonisDBDaniel Baltrukonis
- Adrienne Clements-EganACAdrienne Clements-Egan
- Kathy DelariaKDKathy Delaria
- George R. GunnGGGeorge R. Gunn
- John LoweJLJohn Lowe
- Mauricio MaiaMMMauricio Maia
- Teresa WongTWTeresa Wong
- 1 January 2011
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 54 (2) , 351-358
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Nonclinical development of biopharmaceuticalsDrug Discovery Today, 2009
- Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studiesRegulatory Toxicology and Pharmacology, 2009
- Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic studyJournal of Immunological Methods, 2009
- Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology productsJournal of Immunological Methods, 2008
- A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugsNature Biotechnology, 2007
- A high throughput electrochemiluminescent cell-binding assay for therapeutic anti-CD20 antibody selectionJournal of Immunological Methods, 2006
- The role of the CD40 pathway in the pathogenesis and treatment of cancerCurrent Opinion in Pharmacology, 2004
- Prospects for CD40-directed experimental therapy of human cancerCancer Gene Therapy, 2002
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Phase I Study of Recombinant Human CD40 Ligand in Cancer PatientsJournal of Clinical Oncology, 2001